Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - medRxiv, 2021 - medrxiv.org
… the older adults than in younger adults. The unadjuvanted HD formulation generated similar
reactogenicity profiles … , 28-31 and compared to the reactogenicity profiles reported for other …
reactogenicity profiles … , 28-31 and compared to the reactogenicity profiles reported for other …
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …
PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
… achieve a robust immune response compared with antigen alone, … group as older adults are
less likely than younger adults to … study, with the aim of improving the reactogenicity profile. …
less likely than younger adults to … study, with the aim of improving the reactogenicity profile. …
A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
… than at the 7.5 μg dose in older adults after a single dose (compared at Day 29 in the two-…
Taken collectively, the favorable safety and immunogenicity profiles support further clinical …
Taken collectively, the favorable safety and immunogenicity profiles support further clinical …
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1 …
W Guo, K Duan, Y Zhang, Z Yuan, YB Zhang… - …, 2021 - thelancet.com
… This study reported safety profile … studies indicated that the safety profile of vaccines against
the COVID-19 was similar or even better among older adults compared with younger adults …
the COVID-19 was similar or even better among older adults compared with younger adults …
… to a mammalian cell-based, MF59-adjuvanted, A/H5N1, pandemic influenza vaccine across four phase II/III clinical trials in healthy children, adults, and older adults
E Versage, E van Twuijver, W Jansen, A Theeuwes… - Vaccines, 2021 - mdpi.com
… Here we report immunogenicity and safety analyses of a mammalian cell-based, MF59-adjuvanted,
A/H5N1 vaccine across four clinical trials of similar design, comparing responses to …
A/H5N1 vaccine across four clinical trials of similar design, comparing responses to …
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged≥ 50 years: a randomized …
…, UK Buchwald, V114-020 PNEU-TRUE study group - Vaccine, 2022 - Elsevier
… the older age groups (65–74 and ≥ 75 years) compared with … of age, sex, race, and ethnicity,
the immunogenicity profile … and the safety profile of the V114 combined lots compared with …
the immunogenicity profile … and the safety profile of the V114 combined lots compared with …
… 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults
CA Shaw, A August, S Bart, PGJ Booth, C Knightly… - Vaccine, 2023 - Elsevier
… demonstrated favorable safety and reactogenicity profiles at all … Infants, older adults, and
immunocompromised individuals … note that direct comparison of the data in this study to those …
immunocompromised individuals … note that direct comparison of the data in this study to those …
Comparative postmarket safety profile of adjuvanted and high-dose influenza vaccines in individuals 65 years or older
AJ Pillsbury, P Fathima, HE Quinn… - JAMA network …, 2020 - jamanetwork.com
… superior immunogenicity and offer improved effectiveness in older … comparison of these 2
enhanced influenza vaccines used in older adults, and only 1 other postmarketing comparison …
enhanced influenza vaccines used in older adults, and only 1 other postmarketing comparison …
[HTML][HTML] Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults …
… (18–49 years of age) and older adults (≥50 years of age) [13… of V114 compared with
PCV13, followed by administration of … , V114 was generally well tolerated, with a safety profile …
PCV13, followed by administration of … , V114 was generally well tolerated, with a safety profile …
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older …
V Shinde, I Cho, JS Plested, S Agrawal… - The Lancet Infectious …, 2022 - thelancet.com
… study In this phase 3, randomised clinical trial of 2654 older adults, the safety and immunogenicity
of … qNIV showed an acceptable safety profile, and immunological non-inferiority to IIV4 …
of … qNIV showed an acceptable safety profile, and immunological non-inferiority to IIV4 …